Oligoclonal T cells in human cancer

Medical Oncology

Volumn 15, Issue 4, 1998, Pages 203-211

  Halapi, Eva ^a  

^a DECODE GENETICS   (Iceland)

Author keywords

Idiotype; Melanoma; Multiple myeloma; T cell receptor; Tumor associated antigen; Tumor infiltrating lymphocytes

Indexed keywords

T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER IMMUNOLOGY; CELL CLONE; CYTOTOXIC T LYMPHOCYTE; HUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0032457538     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787202     Document Type: Review

References (104)

1. Danska JS, Livingstone AM, Paragas V, Ishihara T, Fathman CG. The presumptive CDR3 regions of both T cell receptor alpha and beta chains determine T cell specificity for myoglobin peptides. J Exp Med 1990; 172: 27-33.
2. Garboszi DN et al. Structure of the complex between human T-cell receptor viral peptide and HLA-A2. Nature 1996; 384: 134-141.
3. Garcia KC et al. An alpha-beta receptor T cell receptor structure 2.5 A and its orientation in the TCR-MHC complex. Science 1996; 274: 209-219.
4. Shaw AS, Dustin ML. Making the T cell receptor go the distance: a topological view of T cell activation. Immunity 1997; 6: 361-369.
5. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76: 263-274.
6. Chan AC, Iwashima M, Turck CW, Weiss A. Zap-70: a 70 Kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992; 71: 649-662.
7. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15: 321-331.
8. Shaw AS et al. Short related sequences in the cytoplasmic domains of CD4 and CDS mediate binding to the aminoterminal domain of the p561ck tyrosine protein kinase. Mol Cell Biol 1990; 10: 1853-1862.
9. Baccala R, Kono DH, Walker S, Balderas RS, Theofilopoulos AN. Genomically imposed and somatically modified human thymocyte V beta gene repertoires. Proc Natl Acad Sci USA 1991; 88: 2908-2912.
10. Rowen L, Koop BF, Hood L. The complete 685-kilobase DNA sequence of the human beta T cell receptor locus. Science 1996; 272: 1755-1762.
11. + human peripheral blood T lymphocytes. Eur J Immunol 1991; 21: 819-822.
12. + T cells: evidence that V alpha participates in shaping the peripheral T-cell repertoire. J Exp Med 1991; 174: 639-648.
13. Arden B, Clark SP, Kabelitz D, Mak TW. Human T-cell receptor variable gene segment families. Immunogenetics 1995; 42: 455-500.
14. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395.
15. Pullen AM, Marrack P, Kappler JW. The T-cell repertoire is heavily influenced by tolerance to polymorphic self-antigens. Nature 1988; 335: 796-801.
16. Johnson HM, Torres BA, Soos JM. Superantigens: structure and relevance to human disease. Proc Soc Exp Biol Med 1996; 212: 99-109.
17. Choi Y et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med 1990; 172: 981-984.
18. Gulwani-Akolkar B, Akolkar PN, Gregersen PK, Silver J. Analysis of the peripheral blood T-cell receptor repertoire in monozygotic twins discordant for rheumatoid arthritis. Ann N Y Acad Sci 1995; 756: 176-178.
19. Loveridge JA, Rosenberg WM, Kirkwood TB, Bell JI. The genetic contribution to human T-cell receptor repertoire. Immunology 1991; 74: 246-250.
20. Raaphorst FM et al. Usage of TCRAV and TCRBV gene families in human fetal and adult TCR rearrangements. Immunogenetics 1994; 39: 343-350.
21. + T cell clones in elderly humans. J Immunol 1997; 158: 4493-4499.
22. Pannetier C, Even J, Kourilsky P. T-cell repertoire diversity and clonal expansions in normal and clinical samples. Immunol Today 1995; 16: 176-181.
23. Kayser C, Waase I, Weyand CM, Goronzy JJ. T cell receptor germline gene segments and HLA haplotypes control the length of the CDR3 of human T cell receptor beta chains. Cell Immunol 1996; 168: 235-242.
24. Akolkar PN, Gulwani-Akolkar B, McKinley M, Fisher SE, Silver J. Comparisons of T cell receptor (TCR) V beta repertoires of lamina propria and peripheral blood lymphocytes with respect to frequency and oligoclonality. Clin Immunol Immunopathol 1995; 76: 155-163.
25. Dunn DA et al. T-cell receptor V beta expression in normal human skin. Proc Natl Acad Sci USA 1993; 90: 1267-1271.
26. Gross GG et al. Distribution of dominant T cell receptor beta chains in human intestinal mucosa. J Exp Med 1994; 180: 1337-1344.
27. Ahangari G et al. RT-PCR based analysis of T-cell receptor B variable region gene usage in normal human breast skin resident T lymphocytes. Scand J Immunol 1996; 44: 330-334.
28. Alam A et al. Persistence of dominant T cell clones in synovial tissues during rheumatoic arthritis. J Immunol 1996; 156: 3480-3485.
29. + T cells. J Exp Med 1995; 181: 1863-1868.
30. Gulwani-Akolkar B et al. Selective expansion of specific T cell receptors in the inflamed colon of Crohn's disease. J Clin Invest 1996; 98: 1344-1354.
31. Paliard X et al. Evidence for the effects of a superantigen in Rheumatoid arthritis. Science 1991; 253: 325-329.
32. + T cells in acute infectious mononucleosis. Nature Med 1996; 2: 906-911.
33. + T cells with a predominant V beta usage during the primary immune response to HIV. Nature 1994; 370: 463-467.
34. + T cell repertoire in normal subjects and monozygotic twins: implications for studies of infectious and autoimmune diseases. Mol Med 1995; 1: 612-624.
35. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to 'benign monoclonal gammapathy'. J Exp Med 1994; 179: 609-618.
36. + T cell population of rheumatoid arthritis patients. J Immunol 1996; 156: 852-858.
37. Burrows SR et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med 1995; 182: 1703-1715.
38. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995; 80: 695-705.
39. Secarz EE et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993; 11: 729-766.
40. Koopmann JO, Hammerling GJ, Momburg F. Generation, intracellular transport and loading of peptides associated with MHC class I molecules. Curr Opin Immunol 1997; 9: 80-88.
41. Hedrick SM et al. Selection of amino acid sequences in the beta chain of the T cell antigen receptor. Science 1988; 239: 1541-1544.
42. MacDonald HR, Casanova JL, Maryanski JL, Cerottini JC. Oligoclonal expansion of major histocompatibility complex class I-restricted cytolytic T lymphocytes during a primary immune response in vivo: direct monitoring by flow cytometry and polymerase chain reaction. J Exp Med 1993; 177: 1487-1492.
43. McHeyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. Science 1995; 268: 106-111.
44. Argaet VP et al. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med 1994; 180: 2335-2340.
45. Kuwana M, Medsger Jr TA, Wright TM. Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope. J Immunol 1997; 158: 485-491.
46. Grunewald J et al. Blood 1998; in press.
47. de Campos-Lima PO, Levitsky V, Imreh MP, Gavioli R, Masucci MG. Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med 1997; 186: 83-89.
48. Gaudin C et al. In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma. Cancer Res 1995; 55: 685-690.
49. Mouri T et al. T cell receptor V alpha and V beta gene usage by tumour-infiltrating lymphocytes in oral squamous cell carcinoma. Cancer Immunol Immunother 1996; 43: 10-18.
50. Puisieux I et al. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions. Int J Cancer 1996; 66: 201-208.
51. Puisieux I et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. J Immunol 1994; 153: 2807-2818.
52. thor Straten P, Scholler J, Hou-Jensen K, Zeuthen J. Preferential usage of T-cell receptor alpha beta variable regions among tumor-infiltrating lymphocytes in primary human malignant melanomas. Int J Cancer 1994; 56: 78-86.
53. Valteau D et al. T-cell receptor repertoire in neuroblastoma patients. Cancer Res 1996; 56: 362-369.
54. Weidmann E, Elder EM, Trucco M, Lotze MT, Whiteside TL. Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. Int J Cancer 1993; 54: 383-390.
55. Yamamoto Y et al. Cytotoxic activity and T cell receptor repertoire in tumor-infiltrating lymphocytes of adrenal cell carcinomas. Cancer Immunol Immunother 1993; 37: 163-168.
56. Nitta T, Kiyoshi S, Okumura K, Steinmann L. Predominant expression of T cell receptor Vα7 in tumor infiltrating lymphocytes of uveal melanomas. Science 1990; 249: 672-674
57. Salvi S et al. Overexpression of the T-cell receptor beta-chain variable region TCRBV14 in HLA-A2-matched primary human melanomas. Cancer Res 1995; 55: 3374-3379.
58. Sensi M et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. Proc Natl Acad Sci USA 1995; 92: 5674-5678.
59. thor Straten P, Becker JC, Seremet T, Brocker EB, Zeuthen J. Clonal T cell responses in tumor infiltrating lymphocytes from both regressive and progressive regions of primary human malignant melanoma. J Clin Invest 1996; 98: 279-284.
60. Duncan SR, Elias DJ, Roglic M, Pekny KW, Theofilopoulos AN. T-cell receptor biases and clonal proliferations in blood and pleural effusions of patients with lung cancer. Hum Immunol 1997; 53: 39-48.
61. Ebato M, Nitta T, Yagita H, Sato K, Okumura K. Shared amino acid sequences in the ND beta N and N alpha regions of the T cell receptors of tumor-infiltrating lymphocytes within malignant glioma. Eur J Immunol 1994; 24: 2987-2992.
62. Ferradini L et al. Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest 1993; 91: 1183-1190.
63. Weidmann E, Whiteside TL, Giorda R, Herberman RB, Trucco M. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma. Cancer Res 1992; 52: 5913-5920.
64. Velotti F et al. Clonality of tumor-infiltrating lymphocytes in human urinary bladder carcinoma. J Immunother 1997: 20: 470-478.
65. Yamamoto K et al. Accumulation of distinct T cell clonotypes in human solid tumors. J Immunol 1995; 154: 1804-1809.
66. Caignard A et al. In situ demonstration of renal-cell-carcinoma-specific T-cell clones. Int J Cancer 1996; 66: 564-570.
67. Stephens M, Lim K, Stephens P, Thomas DW, Lim SH. Molecular characterisation of tumour infiltrating lymphocytes in oral squamous cell carcinoma. Cancer Immunol Immunother 1998; 46: 34-40.
68. Yosino I et al. Oligoclonal T lymphocytes infiltrating human lung cancer tissue. Int J Cancer 1991; 47: 654-658.
69. Mackensen A et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 1994; 93: 1397-1402.
70. Birck A et al. Analysis of T cell receptor AV and BV chain gene expression by infiltrating lymphocytes in spitz naevi and in halo naevi. Melanoma Res 1997; 7: 49-57.
71. Hishii M et al. In vivo accumulation of the same antimelanoma T cell clone in two different metastatic sites. Proc Natl Acad Sci USA 1997; 94: 1378-1383.
72. Kumar A, Farace F, Gaudin C, Triebel F. Clonal T cell expansion induced by interleukin 2 therapy in blood and tumors. J Clin Invest 1996; 97: 1219-1226.
73. - T cells are induced in responding B cell lymphoma patients treated with Campath-1H(anti-CD52). Eur J Haematol 1997; 58: 5-13.
74. Sensi M et al. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest 1997; 99: 710-717.
75. Sensi M et al. Intralesional selection of T cell clonotypes in the immune response to melanoma antigens occurring during vaccination. J Immunother 1998; 21: 198-204.
76. Garrido F et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997; 18: 89-95.
77. Pawelec G, Zeuthen J, Kiessling R. Escape from host-antitumor immunity. Crit Rev Oncol 1997; 8: 111-141.
78. Yi Q, Österborg A. Idiotype-specific T cells in myltiple myeloma: targets for an immunotherapeutic invention?. Med Oncol 1996; 13: 1-7.
79. - and CD4-specific T-cell responses. Blood 1998; 91: 2459-2466.
80. Yi Q et al. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies. Blood 1995; 86: 3043-3049.
81. Bergenbrant S et al. Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Br J Haematol 1996; 92: 840-846.
82. Hsu FJ et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma. Long-term results of a clinical trial. Blood 1997; 89: 3129-3135.
83. Brown RD, Yuen E, Nelson M, Gibson J, Joshua D. The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma. Leukemia 1997; 11: 1312-1317.
84. + T cell expansions are found preferentially in patients with a low tumor burden. Eur J Immunol 1997; 27: 2245-2252.
85. + T cells in patients with multiple myeloma and paraproteinemia. Blood 1996; 87: 3297-3306.
86. Farace F et al. T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol 1994; 153: 4281-4290.
87. + T cell subsets in chronic lymphocytic leukemia. J Immunol 1997; 158: 1482-1489.
88. Kluin-Nelemans JC et al. Persistent clonal excess and skewed T-cell repertoire in T cells from patients with hairy cell leukemia. Blood 1996; 87: 3795-3802.
89. Van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-693.
90. - CTL lines. Scand J Immunol 1994; 40: 591-600.
91. Slamon DJ et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
92. Peoples GE, Davey MP, Goedegebuure PS, Schoof DD, Eberlein TJ. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer. J Immunol 1993; 151: 5472-5480.
93. + ovarian cancers. J Immunol 1994; 152: 4993-4999.
94. Yasumura S et al. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck. Int J Cancer 1994; 57: 297-305.
95. Sensi M et al. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone. J Exp Med 1993; 178: 1231-1246.
96. Jantzer P, Schendel DJ. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 1998; 58: 3078-3086.
97. Leong SP et al. T cell receptor usage by cytotoxic T lymphocytes against autologous human melanoma. Anticancer Res 1996; 16: 3355-3361.
98. Nishimura MI et al. T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines. J Immunother 1994; 16: 85-94.
99. + HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens. Int J Cancer 1997; 72: 403-407.
100. Romero P et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted melan-A/MART-1 antigenic peptide in melanoma. J Immunol 1997: 159: 2366-2374.
101. Cole DJ, Wilson MC, Rivoltini L, Custer M, Nishimura MI. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes. Cancer Res 1997; 57: 5320-5327.
102. Romero P et al. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J Exp Med 1995; 182: 1019-1028.
103. Visseren MJ et al. Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitope. Int J Cancer 1997; 72: 1122-1128.
104. Farina C, van der Bruggen P, Boel P, Parmiani G, Sensi M. Conserved TCR usage by HLA-Cw * 1601-restricted T cell clones recognizing melanoma antigens. Int Immunol 1996; 8: 1463-1466.